Ruben Rizzi

Mainz, RP, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Phase 3 Randomized Study Investigating the Safety, Tolerability, and Immunogenicity of a Combination Modified Messenger RNA Vaccine Against Influenza and COVID-19 in Healthy Adults.

Phase 3 Randomized Study Investigating the Safety, Tolerability, and Immunogenicity of a Combination Modified Messenger RNA Vaccine Against Influenza and COVID-19 in Healthy Adults.

Journal: Vaccines

Published: July 02, 2026

Generative AI: a generation-defining shift for biopharma regulatory affairs.

Generative AI: a generation-defining shift for biopharma regulatory affairs.

Journal: Nature reviews. Drug discovery

Published: June 25, 2025

A plain language summary of the available safety data for the BNT162b2 COVID-19 vaccine: development, approval, and surveillance of use.

A plain language summary of the available safety data for the BNT162b2 COVID-19 vaccine: development, approval, and surveillance of use.

Journal: Expert review of vaccines

Published: April 04, 2025

A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine.

A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine.

Journal: Vaccine

Published: April 23, 2024

Developing variant-adapted COVID-19 vaccines to improve protection against Omicron and other recent variants: a plain language summary.

Developing variant-adapted COVID-19 vaccines to improve protection against Omicron and other recent variants: a plain language summary.

Journal: Expert review of vaccines

Published: April 05, 2024

Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data.

Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data.

Journal: Human vaccines & immunotherapeutics

Published: February 26, 2024

A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics.

A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics.

Journal: Nature reviews. Drug discovery

Published: November 29, 2023

Regulatory agilities impacting review timelines for Pfizer/BioNTech's BNT162b2 mRNA COVID-19 vaccine: a retrospective study.

Regulatory agilities impacting review timelines for Pfizer/BioNTech's BNT162b2 mRNA COVID-19 vaccine: a retrospective study.

Journal: Frontiers in medicine

Published: August 10, 2023

Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era.

Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era.

Journal: Expert review of vaccines

Published: July 07, 2023

Clinical development and approval of COVID-19 vaccines.

Clinical development and approval of COVID-19 vaccines.

Journal: Expert review of vaccines

Published: February 14, 2022

IABS/CEPI platform technology webinar: Is it possible to reduce the vaccine development time?

IABS/CEPI platform technology webinar: Is it possible to reduce the vaccine development time?

Journal: Biologicals : journal of the International Association of Biological Standardization

Published: April 15, 2021

Showing 1-11 of 11

Last Updated: 09/26/2026